XNCR
Xencor IncNASDAQ
Healthcare • Biotechnology
Factor tilt: Mid-Cap Momentum
$35.75+4.99%
Close Nov 6, 2026
- Market cap
- $2.65B
- 1 month
- +45.9%
- 3 months
- +65.7%
- 1 year
- +148.8%
- 52-week range
- $10.41$35.75
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.34Quarter to Sep 30, 2026 · 12 analysts · revenue $62.99M · +13.7% in 30d
- Short interest
- 22.6% of float12.3M shares · settled Oct 15, 2026 · -25.1% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $104.97M
- Net income
- -$163.33M
- Free cash flow
- -$208.29M
- Book value
- $503.23M
- Total debt
- $65.21M
- P/E
- —
- Price / sales
- 25.2×
- Price / book
- 5.3×
- FCF yield
- -7.9%
- Net margin
- -155.6%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases.
Read more
The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
- Website
- xencor.com
- Headquarters
- Pasadena, CA, United States
- Employees
- 260
- Listed
- Dec 3, 2013
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 24, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 5, 2026 | $51.2M | +17.5% | 100.0% | -$37.1M | -$21.7M |
| Mar 2026filed May 6, 2026 | $4.5M | -86.2% | 43.2% | -$77.9M | -$128.9M |
| Dec 2025filed Feb 25, 2026 | $28.2M | -59.7% | 90.9% | -$53.6M | -$6.7M |
| Sep 2025filed Nov 5, 2025 | $21.0M | +18.0% | -158.9% | -$47.5M | -$6.0M |
| Jun 2025filed Aug 6, 2025 | $43.6M | +157.1% | 93.9% | -$33.2M | -$30.8M |
| Mar 2025filed May 7, 2025 | $32.7M | +104.6% | 91.8% | -$43.2M | -$48.4M |
| Dec 2024filed Feb 27, 2025 | $70.0M | +37.4% | — | $4.0M | -$53.5M |
| Sep 2024filed Nov 6, 2024 | $17.8M | -69.9% | -227.2% | -$55.2M | -$46.3M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Feb 25, 2026 | $125.6M | +13.7% | 91.6% | -$177.5M | -$91.9M |
| Dec 2024filed Feb 27, 2025 | $110.5M | -34.4% | -106.1% | -$178.4M | -$232.6M |
| Dec 2023filed Feb 29, 2024 | $168.3M | +2.3% | -50.6% | -$138.6M | -$126.1M |
| Dec 2022filed Feb 27, 2023 | $164.6M | -40.2% | — | -$82.5M | -$55.2M |
| Dec 2021filed Feb 24, 2022 | $275.1M | +124.2% | — | $43.8M | $82.6M |
| Dec 2020filed Feb 24, 2021 | $122.7M | -21.7% | — | -$76.8M | -$63.5M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched XNCR. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
12,266,541 shares short
-4,102,334 shares (-25.1%) vs Sep 30, 2026
22.6% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
16,368,875 shares short
+617,431 shares (+3.9%) vs Sep 15, 2026
30.2% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
15,751,444 shares short
+838,368 shares (+5.6%) vs Aug 31, 2026
28.9% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
14,913,076 shares short
+724,256 shares (+5.1%) vs Aug 14, 2026
27.4% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
14,188,820 shares short
+2,844,314 shares (+25.1%) vs Jul 31, 2026
26% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
11,344,506 shares short
+502,335 shares (+4.6%) vs Jul 15, 2026
20.8% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind XNCR’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if XNCR is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
33 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Sep 22, 2026
Smart-money 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 8
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
208 filers reported a long position in XNCR for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
69.2%
of the 84.2M shares 13-F filers reported
Moves vs Q1 2026
5 added2 trimmed
3 unchanged
Net shares held
+2%
across the 10 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | BlackRock, Inc. | $219.8M · 13.7M shares | 13.7M | +4.7% |
| 2 | PRIMECAP MANAGEMENT CO/CA/ | $163.9M · 10.2M shares | 10.2M | -1.5% |
| 3 | BVF INC/IL | $114.9M · 7.1M shares | 7.1M | Unchanged |
| 4 | RTW INVESTMENTS, LP | $109.1M · 6.8M shares | 6.8M | Unchanged |
| 5 | RA CAPITAL MANAGEMENT, L.P. | $84.9M · 5.3M shares | 5.3M | +7.7% |
| 6 | STATE STREET CORP | $79.8M · 5M shares | 5M | +13.8% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | $52.8M · 3.3M shares | 3.3M | +5.7% |
| 8 | TCG Crossover Management, LLC | $39.5M · 2.5M shares | 2.5M | Unchanged |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | $37.9M · 2.4M shares | 2.4M | +51% |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | $35.7M · 2.2M shares | 2.2M | -36.7% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of XNCR file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Nov 6, 2026 | PRIMECAP MANAGEMENT CO/CA/13G · passive · amended | 13.29% |
| Oct 30, 2026 | VANGUARD CAPITAL MANAGEMENT LLC13G · passive · amended | 4.99%under 5% |
| Oct 27, 2026 | BlackRock, Inc.13G · passive · amended | 14.5% |
| May 15, 2026 | EcoR1 Capital, LLC13G · passive · amended | 2.9%under 5% |
| Mar 30, 2026 | RA CAPITAL MANAGEMENT, L.P.13G · passive | 6.5% |
| Mar 27, 2026 | VANGUARD GROUP INC13G · passive · amended | 0%under 5% |
Get the Full Analysis for XNCR
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.